YKL-40 is marker of mortality in hospitalized patients

YKL-40 is marker of mortality in hospitalized patients
For patients admitted to the hospital, the inflammatory biomarker YKL-40 is a strong predictor of mortality, regardless of diagnosis, according to a study published online Nov. 12 in the Journal of Internal Medicine.

(HealthDay)—For patients admitted to the hospital, the inflammatory biomarker YKL-40 is a strong predictor of mortality, regardless of diagnosis, according to a study published online Nov. 12 in the Journal of Internal Medicine.

In an effort to examine the of YKL-40 in an unselected patient population, Naja Dam Mygind, M.D., from Rigshospitalet in Copenhagen, Denmark, and colleagues analyzed from 1,407 consecutive acute patients (>40 years) admitted to hospital during a one-year period. Patients were followed for a median of 11.47 years.

The researchers found that, compared with healthy controls, median YKL-40 was significantly increased in patients (157 versus 40 µg/L). Compared with patients with YKL-40 in the lowest quartile, those with YKL-40 in the highest quartile had a significantly elevated hazard ratio (HR) for all-cause mortality in the first year (HR, 7.1) and in the total study period (HR, 3.4). Compared to patients with YKL-40 below the normal age-corrected 95-percentile, patients with YKL-40 above that level had a significantly increased risk of death (HRs, 2.1 after one-year and 1.5 during the total study period). Based on multivariate analysis, YKL-40 was an independent of mortality, which was most significant in the first year, and was a marker of in all disease categories. Independent of disease type, the HR for death was increased for those with YKL-40 above the 95th percentile, compared with healthy subjects.

"The level of YKL-40 at admission is a strong predictor of overall mortality, independent of diagnosis, and could be useful as a biomarker in the acute evaluation of all patients," the authors write.

One author is listed on a European patent relating to YKL-40. Quidel provided some of the YKL-40 assay kits.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Gene variant increases risk of asthma

Apr 10, 2008

A tiny variation in a gene known as CHI3L1 increases susceptibility to asthma, bronchial hyperresponsiveness and decline in lung function, researchers report early online in the New England Journal of Medicine. (The p ...

Statin use at cancer diagnosis linked to lower mortality

Nov 08, 2012

(HealthDay)—For patients with cancer, statin use prior to diagnosis correlates with reduced all-cause and cancer-related mortality, according to a study published in the Nov. 8 issue of the New England Jo ...

Glucose levels at admission predict death in pneumonia

May 30, 2012

(HealthDay) -- For patients with community-acquired pneumonia without preexisting diabetes, serum glucose levels at admission are predictive of death at 28 and 90 days, according to a study published online ...

Recommended for you

Brain neuroinflammation seen in chronic fatigue syndrome

Apr 11, 2014

(HealthDay)—Neuroinflammation markers are elevated in the brains of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) patients compared to healthy controls, according to a study published online ...

Which asthma drugs, dosages work best for African Americans?

Feb 19, 2014

The University of Illinois at Chicago has received funding from the National Institutes of Health to determine what combination and dosages of asthma medications works best to manage asthma in African Americans, who suffer ...

User comments